背景簡介：
在絕經(jīng)婦女、骨固定引起的骨質流失患者、多重骨髓瘤患者Sclerostin水平顯著升高。經(jīng)甲狀旁腺素（PTH）和雌性激素持續(xù)治療后，血清Sclerostin水平降低。隨著Sclerostin和DKK-1中和抗體的開發(fā)研究，有望對于骨代謝疾病治療，獲得新進展。
產品優(yōu)勢：

1. 充分驗證可用于人血清、血漿樣本檢測。（尿標本檢測參照對應的protocol）
2. 樣本量小，只需20ul
3. 高靈敏度-正常值介于標準曲線，標準品2和標準品3值之間。
4. 6個校準品+1個對照（標準品和對照均為人血清基質，檢測結果相關性更好）
5. 即用型檢測試劑盒

試劑盒特點：
1）檢測方法：夾心ELISA,HRP/TMB顯色系統(tǒng)
2）樣本類型：血清、血漿（EDTA或肝素抗凝）、尿樣（參照對應的protocol）
3）樣品量：20ul/test
4）標準品范圍：0-240 pmol/L
5）檢測靈敏度：2.6pmol/L
6）孵育條件：overnight/1h/30min（Room temperature）
7）單位轉換：1pg/ml=0.044pmol
參考文獻：

1. Sclerostin: another bone-related protein related to all-cause mortality in haem dialysis? Viaene L et al., Nephrol Dial Transplant, 2013; 10.1093/ndt/gft039
2. The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD. Pelletier S et al., Clin J Am Soc Nephrol, 2013; 8: 819-823
3. Serum Sclerostin levels are associated with aortic valve calcification in prevalent ha-emodialysis patients. Türkvatan A et al., Nephrol Dial Transplant, 2013; 28: i19–i21
4. Circulating Sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S et al., Calcif Tissue Int, 2012; 90(6): 473-480
5. Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. Gennari L et al., J Clin Endo Metab, 2012; 97: 1737-1744
6. Sclerostin and DKK-1 levels in pre-dialyisis CKD patients. Behets G et al., Nephrol Dial Transplant, 2012; 27: ii36-ii37